BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35005158)

  • 1. Patient experiences of conservative treatment for early stage endometrial cancer and endometrial hyperplasia with atypia using levonorgestrel intrauterine device: A qualitative study.
    O'Hara M; Janda M; McCarthy AL; Nicklin J; Walker G; Obermair A
    Gynecol Oncol Rep; 2022 Feb; 39():100914. PubMed ID: 35005158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial.
    Janda M; Robledo KP; Gebski V; Armes JE; Alizart M; Cummings M; Chen C; Leung Y; Sykes P; McNally O; Oehler MK; Walker G; Garrett A; Tang A; Land R; Nicklin JL; Chetty N; Perrin LC; Hoet G; Sowden K; Eva L; Tristram A; Obermair A
    Gynecol Oncol; 2021 Apr; 161(1):143-151. PubMed ID: 33762086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial.
    Hawkes AL; Quinn M; Gebski V; Armes J; Brennan D; Janda M; ; Obermair A
    Contemp Clin Trials; 2014 Sep; 39(1):14-21. PubMed ID: 24999075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canadian Contraception Consensus (Part 2 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
    J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canadian Contraception Consensus (Part 1 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N;
    J Obstet Gynaecol Can; 2015 Oct; 37(10):936-42. PubMed ID: 26606712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management.
    Nwanodi O
    Healthcare (Basel); 2017 Jul; 5(3):. PubMed ID: 28698465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
    Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS
    Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
    Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
    Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of Levonorgestrel Intrauterine Device Use vs. Oral or Transdermal Progesterone for Postmenopausal Women Using Estrogen Containing Hormone Therapy.
    Clark K; Westberg SM
    Innov Pharm; 2019; 10(3):. PubMed ID: 34007573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
    Luukkainen T; Toivonen J
    Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal intrauterine devices.
    Rybo G; Andersson K; Odlind V
    Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Chin J; Konje JC; Hickey M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
    Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
    Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy.
    Mandelbaum RS; Ciccone MA; Nusbaum DJ; Khoshchehreh M; Purswani H; Morocco EB; Smith MB; Matsuzaki S; Dancz CE; Ozel B; Roman LD; Paulson RJ; Matsuo K
    Am J Obstet Gynecol; 2020 Jul; 223(1):103.e1-103.e13. PubMed ID: 31978437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
    El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
    Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation.
    Karimi-Zarchi M; Dehghani-Firoozabadi R; Tabatabaie A; Dehghani-Firoozabadi Z; Teimoori S; Chiti Z; Miratashi-Yazdi A; Dehghani A
    Clin Exp Obstet Gynecol; 2013; 40(3):421-4. PubMed ID: 24283179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
    Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
    J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system.
    Kim DH; Seong SJ; Kim MK; Bae HS; Kim M; Yun BS; Jung YW; Shim JY
    J Gynecol Oncol; 2017 Jan; 28(1):e1. PubMed ID: 27670255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
    Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
    Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.